Molecular Aspects of Prostate Cancer with Neuroendocrine Differentiation

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2016 Apr 5

PMID 27041934

Citations 13

Authors

Qi Li

Connie S Zhang

YiFen Zhang

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine differentiation (NED), which is not uncommon in prostate cancer, is increases in prostate cancer after androgen-deprivation therapy (ADT) and generally appears in castration-resistant prostate cancer (CRPC). Neuroendocrine cells, which are found in normal prostate tissue, are a small subset of cells and have unique function in regulating the growth of prostate cells. Prostate cancer with NED includes different types of tumor, including focal NED, pure neuroendocrine tumor or mixed neuroendocrine-adenocarcinoma. Although more and more studies are carried out on NED in prostate cancer, the molecular components that are involved in NED are still poorly elucidated. We review neuroendocrine cells in normal prostate tissue, NED in prostate cancer, terminology of NED and biomarkers used for detecting NED in routine pathological practice. Some recently reported molecular components which drive NED in prostate cancer are listed in the review.

Citing Articles

Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response.

Archer M, Lin K, Kolanukuduru K, Zhang J, Ben-David R, Kotula L Am J Clin Exp Urol. 2025; 12(6):331-351.

PMID: 39839748 PMC: 11744350. DOI: 10.62347/YFRP8901.

Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression.

Fan L, Sudeep K, Qi J Adv Exp Med Biol. 2023; 1433:69-86.

PMID: 37751136 PMC: 11052651. DOI: 10.1007/978-3-031-38176-8_4.

Single-cell RNA sequencing reveals intratumoral heterogeneity and potential mechanisms of malignant progression in prostate cancer with perineural invasion.

Zhang B, Wang S, Fu Z, Gao Q, Yang L, Lei Z Front Genet. 2023; 13:1073232.

PMID: 36712886 PMC: 9875799. DOI: 10.3389/fgene.2022.1073232.

Neuroendocrine Differentiation of Lung Cancer Cells Impairs the Activation of Antitumor Cytotoxic Responses in Mice.

Fosado R, Soto-Hernandez J, Nunez-Anita R, Aceves C, Berumen L, Mendieta I Int J Mol Sci. 2023; 24(2).

PMID: 36674504 PMC: 9865473. DOI: 10.3390/ijms24020990.

A rare case of prostate neuroendocrine tumor: A case report.

Teh S, Inn F, Rizuana I, Wm W Front Oncol. 2022; 12:1009146.

PMID: 36263212 PMC: 9574441. DOI: 10.3389/fonc.2022.1009146.

References

Cai C, Wang H, Xu Y, Chen S, Balk S . Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009; 69(15):6027-32. PMC: 2859723. DOI: 10.1158/0008-5472.CAN-09-0395. View

Gong Y, Chippada-Venkata U, Galsky M, Huang J, Oh W . Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate. 2015; 75(6):616-27. DOI: 10.1002/pros.22945. View

Vashchenko N, Abrahamsson P . Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005; 47(2):147-55. DOI: 10.1016/j.eururo.2004.09.007. View

Scheble V, Braun M, Beroukhim R, Mermel C, Ruiz C, Wilbertz T . ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010; 23(8):1061-7. PMC: 3606550. DOI: 10.1038/modpathol.2010.87. View

Maris J . Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma. Cancer Cell. 2008; 15(1):5-6. DOI: 10.1016/j.ccr.2008.12.008. View

Sciarra A, Di Silverio F, Autran A, Salciccia S, Gentilucci A, Alfarone A . Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int. 2009; 82(2):147-51. DOI: 10.1159/000200789. View

Bonkhoff H . Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol. 2002; 12 Suppl 2:S141-4. DOI: 10.1093/annonc/12.suppl_2.s141. View

Schoenherr C, Anderson D . The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995; 267(5202):1360-3. DOI: 10.1126/science.7871435. View

Nakada S, di SantAgnese P, Moynes R, Hiipakka R, Liao S, COCKETT A . The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res. 1993; 53(9):1967-70. View

10.

Aumuller G, Doll A, Wennemuth G, Dizeyi N, Abrahamsson P, Wilhelm B . Regional distribution of neuroendocrine cells in the urogenital duct system of the male rat. Prostate. 2011; 72(3):326-37. DOI: 10.1002/pros.21437. View

11.

BLASCHKO H, COMLINE R, SCHNEIDER F, Silver M, Smith A . Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature. 1967; 215(5096):58-9. DOI: 10.1038/215058a0. View

12.

Santamaria L, Martin R, Martin J, Alonso L . Stereologic estimation of the number of neuroendocrine cells in normal human prostate detected by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2002; 10(3):275-81. DOI: 10.1097/00129039-200209000-00016. View

13.

Berruti A, Bollito E, Cracco C, Volante M, Ciccone G, Porpiglia F . The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate. 2010; 70(7):718-26. DOI: 10.1002/pros.21104. View

14.

Deng X, He G, Levine A, Cao Y, Mullins C . Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int J Cancer. 2007; 122(1):209-18. DOI: 10.1002/ijc.23053. View

15.

Lapuk A, Wu C, Wyatt A, McPherson A, McConeghy B, Brahmbhatt S . From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012; 227(3):286-97. PMC: 3659819. DOI: 10.1002/path.4047. View

16.

Helpap B . Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer. 2002; 95(7):1415-20. DOI: 10.1002/cncr.10840. View

17.

Mlika M, Zendah I, Braham E, Mezni F . CD56 antibody: old-fashioned or still trendy in endocrine lung tumors. J Immunoassay Immunochem. 2014; 36(4):414-9. DOI: 10.1080/15321819.2014.952444. View

18.

Mehra R, Serebriiskii I, Burtness B, Astsaturov I, Golemis E . Aurora kinases in head and neck cancer. Lancet Oncol. 2013; 14(10):e425-35. PMC: 4139969. DOI: 10.1016/S1470-2045(13)70128-1. View

19.

Evans A, Humphrey P, Belani J, van der Kwast T, Srigley J . Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006; 30(6):684-93. DOI: 10.1097/00000478-200606000-00003. View

20.

Montuenga L, Guembe L, Burrell M, Bodegas M, Calvo A, Sola J . The diffuse endocrine system: from embryogenesis to carcinogenesis. Prog Histochem Cytochem. 2003; 38(2):155-272. DOI: 10.1016/s0079-6336(03)80004-9. View